Press Releases

 
Press Releases
  Date Title and Summary View
Jul 17, 2002
PITTSBURGH, Jul 17, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that it will release its first quarter fiscal 2003 financial results before the market opens on Thursday, July 25, 2002. Mylan management will host a conference call and live Webcast at 10:00 AM EDT to discuss the financial results and relevant c...
Jul 9, 2002
PITTSBURGH, Jul 9, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Nizatidine Capsules, 150 mg and 300 mg. Mylan Nizatidine is the generic equivalent of Reliant Pharmaceuticals' Axid...
Jul 2, 2002
PITTSBURGH, Jul 2, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Applications (ANDAs) for Lisinopril Tablets in 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg strengths and Lisinopril and Hydrochlorothiazide Tablets in 10 mg/12.5 m...
Jun 21, 2002
PITTSBURGH, Jun 21, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Tablets, 50 mg. Mylan's Tramadol product is the generic version of R.W. Johnson Pharmaceutical Research Institute's Ul...
Jun 17, 2002
PITTSBURGH--(BUSINESS WIRE)--June 17, 2002--Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of four cents per share will be paid on July 15, 2002 to shareholders of record June 30, 2002. --30--ad/ny* CONTACT: Mylan Laboratories Inc., Pittsbur...
Jun 11, 2002
PITTSBURGH, Jun 11, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP, 0.025 mg, 0.05 mg, 0.075 mg, 0.088 mg, 0.1 mg, 0.112 mg, 0.125 mg, 0.15 mg, 0.175 mg, 0.2 mg and 0.3 mg. Levothyroxine...
Jun 7, 2002
PITTSBURGH, Jun 7, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it has reached an agreement with 3M Pharmaceuticals for an exclusive supply and distribution agreement to sell Flecainide Acetate Tablets in bottles of 100 of the 50 mg, 100 mg and 150 mg strengths. In addition, UDL Laboratories, Inc., a Myl...
May 8, 2002
PITTSBURGH, May 8, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. announced today that it has named Wendy Cameron, 42, to its Board of Directors, effective May 2, 2002. Ms. Cameron's appointment increases the Board to 11 members. Ms. Cameron served for 18 years as Vice President, Divisional Sales and Governmental Affairs, for Ca...
May 8, 2002
PITTSBURGH, May 8, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that the Board of Directors has authorized the Company to implement a Stock Repurchase Program pursuant to which the Company may repurchase up to ten million or approximately 8% of its outstanding common shares. These purchases will be made from...
May 8, 2002
PITTSBURGH, May 8, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc.(NYSE: MYL) - Financial Highlights: - Net revenues increased 30% to exceed $1.1 billion for the fiscal year and 14% to $282.6 million for the quarter. - Gross profit increased 63% to $623.9 million for the fisc
Page: FirstPrevious ...
106
NextLast
= add release to Briefcase